MedPage Today -- Dabigatran, an investigational oral anticoagulant which does not require laboratory monitoring, may be an ideal anticoagulant for atrial fibrillation patients, especially those in centers that are less adept at managing patients taking warfarin, according to a post-hoc analysis from the 18,000-patient RE-LY trial.
